Fenofibrate And Microvascular Events in Type 1 Diabetes (FAME 1) Trial

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1069147

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Diabetes is one of the commonest cause of blindness in adults. Vision loss, which is irreversible, is a most feared complication of diabetes. A blood fat lowering drug called fenofibrate, available in Australia, has been shown to reduce eye damage in people with Type 2 diabetes by 35-40%, and to prevent eye damage in Type 1 diabetic animal models. This study will evaluate the potential benefits of fenofibrate in 450 adults with Type 1 diabetes who have early diabetic eye damage.

Funded Activity Details

Start Date: 01-01-2014

End Date: 01-01-2018

Funding Scheme: Project Grants

Funding Amount: $2,883,529.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Endocrinology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

clinical research | clinical trial | diabetes | lipids | nephrology | ophthalmology | renal disease | retinopathy

Related Links